amoxicillin/clavulanic acid ab 875 mg - 125 mg compr. pellic.
aurobindo sa-nv - amoxicilline trihydraté 1003,44 mg - eq. amoxicilline 875 mg; acide clavulanique 125 mg - comprimé pelliculé - 875 mg - 125 mg - acide clavulanique 125 mg; amoxicilline trihydraté 1003.44 mg - amoxicillin and enzyme inhibitor
methotrexaat ab 25 mg/ml sol. inj./perf. i.v./i.m./i.artér./i.théc. flac.
aurobindo pharma b.v. - méthotrexate 25 mg/ml - solution injectable/pour perfusion - 25 mg/ml - méthotrexate 25 mg/ml - methotrexate
methotrexaat ab 25 mg/ml sol. inj./perf. i.v./i.m./i.artér./i.théc. flac.
aurobindo pharma b.v. - méthotrexate 25 mg/ml - solution injectable/pour perfusion - 25 mg/ml - méthotrexate 25 mg/ml - methotrexate
methotrexaat ab 25 mg/ml sol. inj./perf. i.v./i.m./i.artér./i.théc. flac.
aurobindo pharma b.v. - méthotrexate 25 mg/ml - solution injectable/pour perfusion - 25 mg/ml - méthotrexate 25 mg/ml - methotrexate
methotrexaat ab 25 mg/ml sol. inj./perf. i.v./i.m./i.artér./i.théc. flac.
aurobindo pharma b.v. - méthotrexate 25 mg/ml - solution injectable/pour perfusion - 25 mg/ml - méthotrexate 25 mg/ml - methotrexate
amoxicillin/clavulanic acid ab 500 mg - 125 mg compr. pellic.
aurobindo sa-nv - amoxicilline trihydraté 573,4 mg - eq. amoxicilline 500 mg; acide clavulanique 125 mg - comprimé pelliculé - amoxicillin and enzyme inhibitor
amoxicillin/clavulanic acid ab 875 mg - 125 mg compr. pellic.
aurobindo sa-nv - amoxicilline trihydraté 1003,44 mg - eq. amoxicilline 875 mg; acide clavulanique 125 mg - comprimé pelliculé - amoxicillin and enzyme inhibitor
tagrisso
astrazeneca ab - osimertinib mesilate - carcinome, poumon non à petites cellules - d'autres agents antinéoplasiques, les inhibiteurs de protéines kinases - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
iressa
astrazeneca ab - géfitinib - carcinome, poumon non à petites cellules - agents antinéoplasiques - iressa est indiqué pour le traitement de patients adultes atteints localement avancé ou métastatique non à petites cellules, le cancer du poumon avec mutations activatrices de l'épiderme-facteur de croissance du récepteur de la tyrosine kinase.
atorvastatin ab 10 mg compr. pellic.
aurobindo sa-nv - atorvastatine calcique trihydraté 10,824 mg - eq. atorvastatine 10 mg - comprimé pelliculé - 10 mg - atorvastatine calcique trihydraté 10.824 mg - atorvastatin